David Brian Perez Net Worth

The estimated Net Worth of David Brian Perez is at least $353 mil dollars as of 10 August 2024. David Perez owns over 11,336 units of Neogenomics stock worth over $352,883 and over the last 5 years David sold NEO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Perez NEO stock SEC Form 4 insiders trading

David has made over 2 trades of the Neogenomics stock since 2019, according to the Form 4 filled with the SEC. Most recently David exercised 11,336 units of NEO stock worth $184,890 on 10 August 2024.

The largest trade David's ever made was exercising 11,336 units of Neogenomics stock on 10 August 2024 worth over $184,890. On average, David trades about 1,659 units every 248 days since 2019. As of 10 August 2024 David still owns at least 21,636 units of Neogenomics stock.

You can see the complete history of David Perez stock trades at the bottom of the page.

What's David Perez's mailing address?

David's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.

Insiders trading at Neogenomics

Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van, eSteven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.

What does Neogenomics do?

neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig

Complete history of David Perez stock trades at Mesa Laboratories e Neogenomics

Neogenomics executives and stock owners

Neogenomics executives and other stock owners filed with the SEC include:

• Douglas VanOort,
  Chairman of the Board, Chief Executive Officer
• Robert Shovlin,
  President - Clinical Services Division
• Lawrence Weiss,
  Chief Medical Officer
• George Cardoza,
  President - Pharma Services Division
• William Bonello,
  President, Informatics and Director of Investor Relations
• Douglas M. Brown,
  Chief Strategy & Corp. Devel. Officer
• Kathryn McKenzie,
  Chief Financial Officer
• Steven Ross,
  Chief Information Officer
• Steven Jones,
  Director
• Alison Hannah,
  Independent Director
• Lynn Tetrault,
  Lead Independent Director
• Raymond Hipp,
  Independent Director
• Bruce Crowther,
  Independent Director
• Kevin Johnson,
  Independent Director
• Stephen Kanovsky,
  Independent Director
• Michael Kelly,
  Independent Director
• Rachel Stahler,
  Director
• Douglas Brown,
  Chief Strategy and Corporate Development Officer
• Denise Pedulla,
  General Counsel, Corporate Secretary
• Jennifer Balliet,
  Vice President, Chief Culture Officer
• Stephanie Bywater,
  Chief Compliance Officer
• Cynthia Dieter,
  Chief Accounting Officer, Controller
• Dr. Steven G. Brodie FACMG, Ph.D.,
  Sr. VP of Laboratory Operations
• George A. Cardoza,
  Pres & COO of Lab Operations
• Marcus B. Silva J.D., M.B.A.,
  Chief Marketing Officer
• Halley E. Gilbert Esq., J.D.,
  Chief Legal Officer
• Charlie Eidson,
  Director of Investor Relations and Corp. Devel.
• John Mooney,
  Chief Technology Officer
• Cynthia J. Dieter,
  Chief Accounting Officer & Controller
• Mark W. Mallon,
  CEO & Director
• William J Robison,
  Director
• Maher Albitar,
  Chief Medical Officer
• Sharon Virag,
  Chief Financial Officer
• David Sholehvar,
  President, Clinical Services
• Neil Gunn,
  Director
• Elizabeth Floegel,
  Director
• Anthony P. Zook,
  Director
• Christopher M Smith,
  Chief Executive Officer
• Mark Alan Machulcz,
  Vice President of Operations
• Michael T Dent,
  Director
• Steven G. Brodie,
  Chief Scientific Officer
• Steven Caspen Select Health...,
  Executive VP of FinanceExecutive VP of Finance
• Robert H. Horel,
  Vice President andGM PathLogic
• Robert P Gasparini,
  Chief Science Officer
• Halley E Gilbert,
  Chief Legal Officer
• Gina M Wallar,
  President, Pharma Services
• Mark Mallon,
  Chief Executive Officer
• Clive Morris,
  President of Inivata
• Oort Douglas M Van,
  Director
• David Daly,
  Director
• Vishal Sikri,
  President Advanced Diagnostics
• David Brian Perez,
  Director
• Jeffrey Scott Sherman,
  Chief Financial Officer
• Shashikant Kulkarni,
  Chief Scientific Officer
• Alicia C Olivo,
  General Counsel
• Melody Harris,
  Chf Ops Off, Pres, Informatics
• Greg D Aunan,
  Chief Accounting Officer
• Warren Stone,
  Chief Commerical Officer